Hansoh Pharma receives approval for HS-10529 tablets

Hansoh Pharmaceutical Group Company Limited (HKEX: 3692) announced that it has received clinical trial approval from China's National Medical Products Administration (NMPA) for its HS-10529 tablets. This Small Molecule Category I Innovative Drug targets KRAS G12D mutations and is self-developed by the Group. The approval will enable Hansoh Pharma to investigate the drug's potential in clinical trials for advanced solid tumors, including pancreatic cancer, colorectal cancer, and non-small cell lung cancer. The announcement was made by order of the Board, with Zhong Huijuan, Chairlady, issuing the statement on April 15, 2025, in Hong Kong.